Logo

CLLS

Cellectis S.A.

CLLS

Cellectis S.A. • NASDAQ
$5.07 ▲ 0.60% (+0.03)
Market Cap $508.55 M
52w High $5.48
52w Low $1.10
Dividend Yield 0%
P/E -15.36
Volume 47.05K
Outstanding Shares 100.30M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $35.172M ▲ $24.774M ▲ $589K ▲ 1.675% ▲ $0.006 ▲ $7.707M ▲
Q2-2025 $16.725M ▲ $23.887M ▲ $-23.735M ▼ -141.913% ▲ $-0.24 ▼ $-16.664M ▼
Q1-2025 $10.655M ▼ $22.819M ▲ $-18.128M ▼ -170.136% ▼ $-0.18 ▼ $-11.285M ▼
Q4-2024 $12.717M ▼ $20.882M ▼ $5.922M ▲ 46.568% ▲ $0.059 ▲ $14.174M ▲
Q3-2024 $16.2M $24.177M $-23.056M -142.321% $-0.23 $-16.475M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $52.243M ▼ $343.045M ▼ $242.567M ▼ $100.478M ▲
Q2-2025 $196.15M ▼ $353.966M ▼ $256.855M ▲ $97.111M ▼
Q1-2025 $241.691M ▼ $364.086M ▼ $247.882M ▼ $116.204M ▼
Q4-2024 $260.306M ▼ $383.544M ▼ $252.511M ▼ $131.033M ▲
Q3-2024 $260.947M $395.876M $266.452M $129.424M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $589K ▲ $-1.571M ▲ $-3.441M ▲ $-4.26M ▲ $-7.566M ▲ $-2.752M ▲
Q2-2025 $-23.735M ▼ $-10.31M ▲ $-52.717M ▼ $-4.271M ▼ $-67.827M ▼ $-10.615M ▲
Q1-2025 $-18.128M ▼ $-17.16M ▼ $4.223M ▲ $-4.09M ▼ $-15.615M ▲ $-17.555M ▼
Q4-2024 $5.922M ▲ $-47K ▲ $-16.661M ▼ $2.925M ▲ $-15.836M ▼ $-1.792M ▲
Q3-2024 $-23.056M $-5.829M $22.333M $-4.218M $10.045M $-6.634M

Five-Year Company Overview

Income Statement

Income Statement Cellectis is still very much a research‑stage company: revenue is tiny and not yet a meaningful driver of the business. The company’s main story remains spending on R&D and operations rather than sales. Losses have been consistent for years, but the most recent year shows some improvement, with operating and net losses narrowing compared with prior years. This suggests better cost control or higher collaboration income, but the path to true profitability still looks distant and will likely depend on successful clinical milestones or partnerships rather than gradual revenue growth from current activities.

Balance Sheet

Balance Sheet The balance sheet is relatively simple and still anchored by cash and other research‑related assets. Total assets have come down over the last several years but ticked up most recently, which is a modest positive sign. Debt is present but not excessive relative to the size of the company, and it has stayed fairly stable. Equity had been eroding as losses accumulated, but there was a small recovery in the latest year. Overall, the company has a limited but real capital base, with a balance sheet that can support ongoing development but not unlimited delays or setbacks.

Cash Flow

Cash Flow Historically, Cellectis has burned cash in its operations, which is normal for a clinical‑stage biotech. The notable change is that operating cash flow turned positive in the latest year, a sharp contrast to the persistent outflows seen before. Free cash flow also moved into positive territory, helped by very low capital spending. This positive swing in cash generation reduces short‑term financing pressure, but it may not be durable if R&D spending ramps up again or if partnership cash is uneven. Long‑term, the business model still relies heavily on external funding, deals, or eventual product success.

Competitive Edge

Competitive Edge Cellectis occupies a focused niche in gene‑edited cell therapies, especially in “off‑the‑shelf” allogeneic CAR‑T treatments. Its long history in gene editing and its proprietary TALEN platform give it a differentiated technical base compared with newer entrants. The company’s intellectual property portfolio, in‑house manufacturing, and partnerships with larger drugmakers strengthen its position and create barriers for some competitors. That said, it operates in an intensely competitive area with many better‑funded players, so its competitive standing will ultimately hinge on clinical data, safety outcomes, and the ability to move programs through late‑stage development.

Innovation and R&D

Innovation and R&D Innovation is the core asset here. Cellectis’s TALEN gene‑editing technology, combined with its focus on allogeneic CAR‑T, aims to make cell therapies more scalable, faster to deliver, and potentially cheaper than patient‑specific approaches. The company has a pipeline of product candidates in blood cancers and is extending its platform into broader gene therapy applications. New work on non‑viral DNA delivery (such as its CssDNA approach) shows it is pushing into next‑generation methods that could improve safety and efficiency. The main risk is classic for biotech: high scientific promise but long, uncertain timelines and heavy dependence on successful trial outcomes.

Summary

Cellectis is a high‑innovation, high‑uncertainty biotechnology story. Financially, it remains loss‑making with barely any recurring revenue, but the trend in the latest year shows better cost control and an improvement in cash flow, which eases near‑term pressure. Its balance sheet and cash position appear adequate for a company at this stage, though not deep enough to absorb many years of setbacks without new funding. The real value driver is the gene‑editing and allogeneic CAR‑T platform, backed by patents, long experience, and strategic partnerships. Future outcomes will likely depend on three things: the strength of upcoming clinical data for its lead programs, the ability to secure additional partnerships or funding on good terms, and how well it can stand out in a crowded field of cell and gene therapy competitors. The profile is typical of a clinical‑stage biotech: potentially significant upside if the science translates into approved products, balanced by substantial execution and scientific risk.

NEWS

November 19, 2025 · 6:18 AM UTC

Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells

Read more

November 7, 2025 · 4:30 PM UTC

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

November 3, 2025 · 9:15 AM UTC

Cellectis to Present a Development Update for eti-cel at ASH 2025

Read more

October 31, 2025 · 4:30 PM UTC

Cellectis to Report Third Quarter Financial Results on November 7, 2025

Read more

October 16, 2025 · 3:19 PM UTC

Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL

Read more